Pharmaceutical companies are increasingly embracing the
need for running trials across multiple sites globally. The
rise of personalised medicine, and its promise of improving
the drug development process and focused, faster approval
of new therapies, places the industry firmly at the centre
of the global genomics initiative. Rodrigo Barnes, Chief
Technology Officer and Pamela Brankin, Head of Marketing
and Communications at Aridhia Informatics Ltd, observe
how capitalising on it requires a combination of technologies
supported and enabled by increased collaboration among
the industry, academia and healthcare providers.

Comments are closed.

%d bloggers like this: